हिंदी में पढ़ें

Zydus Lifesciences

Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical

Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical

Mon, Dec 11, 2023

Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.

Zydus Lifesciences shares extend losses to third day; is there any opportunity?

Zydus Lifesciences shares extend losses to third day; is there any opportunity?

Thu, Sep 21, 2023

Zydus Lifesciences share price NSE: The pharmaceutical company received final approval from the US drug regulator, the US Food and Drug Administration, for its clindamycin phosphate gel, used in the treatment of acne. Clindamycin is an antibiotic which works by stopping the growth of bacteria.

USFDA gives nod to Zydus Lifesciences for generic rheumatoid arthritis treatment drug

USFDA gives nod to Zydus Lifesciences for generic rheumatoid arthritis treatment drug

Thu, Aug 03, 2023

The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing.

TRENDING NOW

Zydus gets USFDA nod to market cancer treatment generic injection

Zydus gets USFDA nod to market cancer treatment generic injection

Thu, Jul 27, 2023

The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.

Zydus Lifesciences gets USFDA nod for generic acne-treating drug

Zydus Lifesciences gets USFDA nod for generic acne-treating drug

Mon, Jun 19, 2023

The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing.

Zydus commences trial to generate data on effect of Saroglitazar Mg in NAFLD patients

Zydus commences trial to generate data on effect of Saroglitazar Mg in NAFLD patients

Fri, Jun 09, 2023

The "Phase IV EVIDENCES- XI" trial will enrol around 1,500 male and female NAFLD patients with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome- 200 patients each), the drug maker said in a regulatory filing.

Zydus gets USFDA nod for generic drug to treat stomach & esophagus problems

Zydus gets USFDA nod for generic drug to treat stomach & esophagus problems

Thu, Jun 08, 2023

Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a generic drug used to treat certain stomach and esophagus problems.

Dividend stocks: ITC, SBI, Zydus Lifesciences, Wheels India, other big announcements

Dividend stocks: ITC, SBI, Zydus Lifesciences, Wheels India, other big announcements

Thu, May 18, 2023

Dividend stocks: Sensex on Thursday finished the volatile session with a loss of 128.9 points or 0.2 per cent at 61,431.7, having gyrated in a range of more than 600 points in intraday trade. The Nifty 50 lost 51.8 points or 0.3 per cent for the day to settle at 18,130, after broadly moving within the 18,100-18,300 band during the session.

Zydus Lifesciences dividend: Drug maker announces 600% payout

Zydus Lifesciences dividend: Drug maker announces 600% payout

Thu, May 18, 2023

Zydus Lifesciences dividend 2023: Zydus Lifesciences announced a final dividend of Rs 6 per equity share of face value of Re 1 i.e., a 600 per cent payout to its shareholders.

Zydus Lifesciences gets USFDA nod for generic medication

Zydus Lifesciences gets USFDA nod for generic medication

Mon, Apr 24, 2023

Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a generic medication that is used to lower triglycerides, in the American market. The company has got the final approval from USFDA to market Icosapent Ethyl Capsules in strength of 0.5 g and 1 g.

Zydus Lifesciences gets USFDA nod to its generic medicine for high blood pressure

Zydus Lifesciences gets USFDA nod to its generic medicine for high blood pressure

Thu, Apr 20, 2023

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic version of metoprolol tartrate tablets used to treat high blood pressure.

Zydus Life shares rise after drug maker gets US regulator's nod for bronchospasm treatment injection

Zydus Life shares rise after drug maker gets US regulator's nod for bronchospasm treatment injection

Mon, Apr 17, 2023

Isoproterenol Hydrochloride injection will be manufactured at the company's injectable manufacturing facility at Jarod, near Vadodara in India. With this, Zydus has received a total of 362 approvals and has so far filed more than 440 ANDAs since starting the filing process in FY 2003-04.

Zydus Lifesciences gets US health regulator's nod for its generic medicine

Zydus Lifesciences gets US health regulator's nod for its generic medicine

Fri, Mar 24, 2023

Doxepin hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level, it added.

Zydus Lifesciences gets USFDA nod to market generic drug

Zydus Lifesciences gets USFDA nod to market generic drug

Tue, Feb 28, 2023

The drug will be manufactured at the Zydus group's formulation manufacturing facility in Moraiya, Ahmedabad. As per IQVIA MAT December 2022 data, Apixaban tablets had annual sales of USD 18,876 million in the US.

Q1 results FY2023: Tata Consumer, Prestige Estates, Zydus Lifesciences, Pidilite declare results - highlights

Q1 results FY2023: Tata Consumer, Prestige Estates, Zydus Lifesciences, Pidilite declare results - highlights

Wed, Aug 10, 2022

Tata Consumer Products Q1 results FY2023: Tata Consumer Products Ltd (TCPL) on Wednesday reported 38.2 per cent rise in consolidated net profit at Rs 276.72 crore for June quarter 2022-23

Buy, Sell or Hold: What should investors do with Vardhman Textiles, Welspun India and Zydus Lifesciences?

Buy, Sell or Hold: What should investors do with Vardhman Textiles, Welspun India and Zydus Lifesciences?

Tue, Jul 19, 2022

After two back-to-back strong closings, the Indian market opened nearly half per cent lower on Tuesday.

Zydus Lifesciences' Rs 750 cr-share buyback to open on June 23

Zydus Lifesciences' Rs 750 cr-share buyback to open on June 23

Tue, Jun 14, 2022

Zydus Lifesciences on Monday said its Rs 750 crore-share buyback offer will commence on June 23 and close on July 6.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x